The ACE-inhibitor lisinopril affects plasma insulin levels but not fibrinolytic parameters.
There is evidence that ACE-inhibitors exert beneficial effects on endogenous fibrinolysis in patients with previous myocardial infarction. It is still unknown if this effect is restricted to this patient group only and by which mechanisms ACE-inhibitors exhibit the profibrinolytic effects. One possible explanation might be the positive influence of ACE-inhibitors on insulin metabolism by decreasing plasma insulin which in turn could decrease PAI-1, a major regulator of the fibrinolytic system. Therefore the present study examines the relationship between insulin and PAI-1 plasma levels during intravenous glucose tolerance tests before and after administration with the ACE-inhibitor lisinopril in 12 male obese patients with angiographically proven coronary artery disease and borderline hypertension. After a 4-weeks wash-out period glucose tolerance tests were performed before and after lisinopril-treatment (10mgs/d) for 12 weeks. After the treatment period, fasting plasma insulin level decreased from 15.6 +/- 2.1 to 11 +/- 1.8 uU/ml, p < or = 0.01. Stimulated levels of insulin during glucose tolerance test also significantly decreased by lisinopril (peak insulin from 57 +/- 10 to 41.2 +/- 7.3 uU/ml, p < or = 0.02). Basal plasma tissue plasminogen activator antigen, PAI-1 total antigen and PAI-1 "active" antigen were unaffected by therapy (8.4 +/- 0.5 vs 8.6 +/- 0.5 ng/ml, 118 +/- 20 vs 124 +/- 16 ng/ml and 21 +/- 7 vs 30 +/- 7 ng/ml, respectively). Our data confirm a beneficial effect of lisinopril on plasma levels of insulin but failed to demonstrate any profibrinolytic effect in this study population, thus questioning the postulated mechanism of influencing endogenous fibrinolysis by changes of plasma insulin.
Zehetgruber
M
M
Department of Cardiology, University of Vienna, Austria.
Beckmann
R
R
Gabriel
H
H
Christ
G
G
Binder
B R
BR
Huber
K
K
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D005342:Fibrinolysis / Q000187:drug effects*; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy*; D007328:Insulin / Q000097:blood*; D017706:Lisinopril / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged
D000806:Angiotensin-Converting Enzyme Inhibitors; D007328:Insulin; D017706:Lisinopril